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OPOBJECTIVES The OPTION (Optimal Anti-Tachycardia Therapy in Implantable Cardioverter-Deﬁbrillator Patients
Without Pacing Indications) trial sought to compare long-term rates of inappropriate shocks, mortality, and morbidity
between dual-chamber and single-chamber settings in implantable cardioverter-deﬁbrillators (ICDs) patients.
BACKGROUND The use of dual-chamber ICDs potentially allows better discrimination of supraventricular arrhythmias
and thereby reduces inappropriate shocks. However, it may lead to detrimental ventricular pacing.
METHODS This prospective multicenter, single-blinded trial enrolled 462 patients with de novo primary or secondary
prevention indications for ICD placement and with left ventricular ejection fractions #40% despite optimal tolerated
pharmacotherapy. All patients received atrial leads and dual-chamber deﬁbrillators that were randomized to be pro-
grammed either with dual-chamber or single-chamber settings. In the dual-chamber setting arm, the PARADþ algorithm,
which differentiates supraventricular from ventricular arrhythmias, and SafeR mode, to minimize ventricular pacing, were
activated. In the single-chamber setting arm, the acceleration, stability, and long cycle search discrimination criteria were
activated, and pacing was set to VVI 40 beats/min. Ventricular tachycardia detection was required at rates between 170
and 200 beats/min, and ventricular ﬁbrillation detection was activated above 200 beats/min.
RESULTS During a follow-up period of 27 months, the time to the ﬁrst inappropriate shock was signiﬁcantly longer in
the dual-chamber setting arm (p ¼ 0.012, log-rank test), and 4.3% of patients in the dual-chamber setting group
compared with 10.3% in the single-chamber setting group experienced inappropriate shocks (p ¼ 0.015). Rates of
all-cause death or cardiovascular hospitalization were 20% for the dual-chamber setting group and 22.4% for the single-
chamber setting group and satisﬁed the pre-deﬁned margin for equivalence (p < 0.001).
CONCLUSIONS Therapy with dual-chamber settings for ICD discrimination combined with algorithms for minimizing
ventricular pacing was associated with reduced risk for inappropriate shock compared with single-chamber settings,
without increases in mortality and morbidity. (Optimal Anti-Tachycardia Therapy in Implantable Cardioverter-Deﬁbrillator
[ICD] Patients Without Pacing Indications [OPTION]; NCT00729703) (J Am Coll Cardiol HF 2014;2:611–9) © 2014 by the
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tachyarrhythmia
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612I mplantable cardioverter-deﬁbrillator (ICD)therapy prevents sudden cardiac deathand prolongs survival in patients who
undergo implantation for primary and sec-
ondary prevention of sudden cardiac death
(1–4). The beneﬁts of the therapy and the
expansion of indications for ICDs since
their introduction have led to a signiﬁcant
increase in the number of ICD recipients andin lives saved by ICD therapy (5).
However, inappropriate therapies, most commonly
caused by supraventricular tachyarrhythmias (SVTs),
remain a signiﬁcant adverse effect of ICD therapy,
affecting up to 40% of patients during long-term
follow-up (6–10). Besides the pain and discomfort
caused by inappropriate shocks, they are also asso-
ciated with anxiety, depression, impaired quality of
life, proarrhythmia, low treatment satisfaction, and
possibly mortality (11–13).SEE PAGE 620Important efforts have been made in deﬁning
optimal programming methods for accurate rhythm
detection and minimizing inappropriate ICD in-
terventions. However, so far, there is no consensus
on the most appropriate programming methodology
(14–17). Likewise, the question of whether dual-
chamber ICD therapy with dual-chamber settings
can reduce the risk for inappropriate shocks in com-
parison with single-chamber therapy with single-
chamber settings remains unanswered. Several
investigators have reported a trend toward fewer
inappropriate shocks with dual-chamber setting (18),
whereas others have reported no differences between
the therapies (19–22). Moreover, additional factors
should be considered when choosing single- versus
dual-chamber ICD settings, including the risk forBoston Scientiﬁc, Medtronic, St. Jude Medical, and Sorin; is a con
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t received March 27, 2014; revised manuscript received May 14, 2complications (23), as well as the detrimental effect of
unnecessary ventricular pacing (24). Therefore, the
potential superiority of dual-chamber over single-
chamber ICD settings in terms of inappropriate
shocks can be assessed only in the light of optimal
tachyarrhythmia discrimination algorithms combined
with optimized bradycardia parameters for mini-
mized ventricular pacing (25).
The OPTION (Optimal Anti-Tachycardia Therapy in
Implantable Cardioverter-Deﬁbrillator Patients With-
out Pacing Indications) trial was designed to compare
long-term outcomes in ICD recipients with dual-
chamber settings with those in patients with single-
chamber settings. All patients received atrial leads
and dual-chamber devices, the only difference being
the pacing mode setting. The programming in both
groups was optimized to minimize ventricular pacing
and to reduce inappropriate shocks using discrimi-
nation algorithms along with standardized anti-
tachycardia pacing (ATP) therapies.
METHODS
TRIAL DESIGN. The rationale and design of OPTION
have been published previously (25). The OPTION
trial is a prospective, randomized, multicenter, 2-
arm, single-blinded, parallel-group trial. A total of
462 patients were enrolled at 54 centers in Europe
and North America between June 2006 and April
2009. Eligible patients were recipients of de novo
ICDs for primary or secondary prevention of sudden
cardiac death with left ventricular ejection
fractions #40% despite optimal tolerated heart
failure therapy. Major exclusion criteria were an
indication for permanent pacemaker or resynchro-
nization therapy; the diagnosis of hypertrophic
obstructive cardiomyopathy or acute myocarditis;sultant for Biotronik and Sorin; and has performed
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613history of percutaneous coronary intervention,
troponin-positive acute coronary syndrome, myocar-
dial infarction, or coronary artery bypass grafting
within the previous month; and permanent atrial
tachyarrhythmias or cardioversion of these within the
previous month.
The investigational plan was approved by the
institutional review board or ethics committee at each
study center. All patients provided written informed
consent. Before implantation, patients were ran-
domized to either standard single-chamber settings
or dual-chamber settings, as described later, accord-
ing to a 4-block permutation randomization list.
Follow-up visits were scheduled at 3 months after
implantation and at 6-month intervals thereafter up
to 27 months.
STUDY ENDPOINTS. The primary endpoint of this
study was 2-fold: the time to ﬁrst occurrence of
inappropriate ICD shock and the occurrence of
all-cause death or cardiovascular hospitalization
(including hospitalization for congestive heart fail-
ure, symptomatic atrial ﬁbrillation (AF), cardiover-
sion of AF, stroke, and undetected or untreated
ventricular tachycardia).
Secondary endpoints were rates of appropriate
and inappropriate ICD shocks, all-cause mortality,
cardiovascular mortality, hospitalization for cardio-
vascular reasons, and mean and median cumulative
percent of ventricular pacing and system-related
complications.
DEVICES AND PROGRAMMING. All patients received
dual-chamber ICDs (OVATIO DR model 6550, Sorin
Group, Milan, Italy). In the dual-chamber setting arm,
the discrimination algorithm PARADþ was activated.
This algorithm differentiates supraventricular from
ventricular arrhythmias on the basis of ventricular
rate stability, rate-onset analysis, atrioventricular
association analysis, long cycle search, and determi-
nation of the chamber of origin in the case of 1:1
tachycardia (26–29). In the single-chamber setting
arm, the acceleration (onset), stability, and long cycle
search discrimination criteria were activated. Ven-
tricular tachycardia detection was required at rates
between 170 and 200 beats/min (353 to 300 ms) with
the delivery of 2 pre-deﬁned sequences of ATP fol-
lowed by shocks. Ventricular ﬁbrillation detection
was activated above 200 beats/min, with shock ther-
apy programmed on being preceded by 1 ATP for
arrhythmias at heart rates between 200 and 240
beats/min (300 to 250 ms). A slow ventricular tachy-
cardia zone was set at 120 beats/min in both groups.
This zone (500 to 353 ms) was used as a monitor zone
for the single-chamber setting group, while ATP withno shock was recommended for the dual-chamber
setting group (24).
In the dual-chamber setting group, SafeR mini-
mized ventricular pacing mode (30) was activated
with a basic rate of 60 beats/min. In the single-
chamber setting arm, a ventricular backup pacing of
VVI 40 beats/min was used.
DATA COLLECTION AND EVALUATION. Data were
collected by paper case report forms and electronic
ﬁles derived from Holter devices at each follow-up
visit. All data considered for the present analysis
were monitored. Adverse events and hospitalizations
were documented on speciﬁc case report forms and
were independently reviewed by a data safety moni-
toring board consisting of 4 electrophysiologists and
heart failure experts responsible for evaluating, vali-
dating, and classifying all adverse events. In addition,
a blinded events committee of 5 experts validated the
appropriateness of shocks on the basis of the analysis
of the electrographic recording ascertained from the
device’s memory. The assessment was performed
blinded to treatment arm, on the basis of the same
information regarding atrioventricular association
analysis (also available in the single-chamber setting
group), electrographic conﬁguration, arrhythmia
onset, and regularity.
STATISTICAL ANALYSES. As the study had 2 primary
endpoints, the signiﬁcance level for each primary
endpoint was set at 0.025. For all other tests, the
signiﬁcance level was set at 0.05. Different pre-
speciﬁed analyses were applied to assess the pri-
mary endpoint: Kaplan-Meier analysis for the time of
ﬁrst occurrence of inappropriate shock with a log-
rank test to validate the difference and a Student t
test for equivalence testing after normal approxima-
tion to assess whether the difference in the occur-
rence of speciﬁc cardiovascular events or death
between randomization groups was less than 17%.
Time-to-event and survival curves were estimated by
using the Kaplan-Meier approach and are displayed as
descriptive graph (11).
For other dichotomous variables, the chi-square
test and the Fisher exact test were used as appro-
priate. Continuous variable were compared using the
Student t test when normal distribution was con-
ﬁrmed; otherwise the Wilcoxon rank test was used.
To identify potential predictors of inappropriate
shocks, univariate and multivariate (using logistic
model) analyses were carried out. Only predictors
with p values <0.10 (on univariate analysis) were
added in the multivariate model.
All endpoint analyses were carried out on the basis
of the intention-to-treat principle. Patients with
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as follows: censored at the time of last follow-up for
survival analysis or assuming none experienced the
outcome of interest for dichotomous variables.
The statistical software used for the analyses was
SAS version 9.2 (SAS Institute Inc., Cary, North
Carolina).
RESULTS
A total of 462 patients were included in the OPTION
trial, and 453 received study devices. The dual-
chamber setting group consisted of 230 patients,
and 223 patients were assigned to the single-chamber
setting group (Figure 1). The clinical characteristics of
the 2 groups at baseline are given in Table 1.
The average follow-up duration was 23.4  7.9
months. During the trial, a total of 47 patients
crossed over from one treatment group to the other:
39 crossed over from the single-chamber setting
group to the dual-chamber setting group and 8 from
the dual-chamber setting group to the single-chamberFIGURE 1 Patient Distribution
AE ¼ adverse event(s); ICD ¼ implantable cardioverter-deﬁbrillator.setting group. Known reasons for crossover from the
single-chamber setting to dual-chamber setting arm
included the occurrence of inappropriate therapies in
13 patients, clinical causes in 5 patients, and pro-
gramming errors in 8 patients. The switch from the
dual-chamber setting arm to the single-chamber
setting arm was explained by lead issues in 2 pa-
tients and programming errors in 3 patients.
PRIMARY ENDPOINTS. The time to ﬁrst inappropriate
shock was signiﬁcantly longer in the dual-chamber
setting group compared with the single-chamber
setting group (p ¼ 0.012, log-rank test) (Figure 2A).
The hazard ratio was 2.5 (95% conﬁdence interval [CI]:
1.2 to 5.3) in favor of dual-chamber setting therapy.
The endpoint of all-cause death or cardiovascular
hospitalizations occurred in 46 patients (20.0%) in
the dual-chamber setting group and 50 (22.4%) in
the single-chamber setting group (Table 2). The
pre-speciﬁed equivalence analysis with a margin of
17% conﬁrmed the equivalence of dual-chamber
setting therapy to single-chamber setting therapy
TABLE 1 Baseline Characteristics of the Study Population
Variable
Dual-Chamber
Setting Group
(n ¼ 230)
Single-Chamber
Setting Group
(n ¼ 223)
Age (yrs) 62.6  10.9 63.9  10.0
Men 186 (85.3%) 189 (86.7%)
Implantation indication
Primary prevention 168 (73.7%) 171 (76.7%)
Secondary prevention 60 (26.3%) 52 (23.3%)
NYHA functional
class I/II/III/IV
16%/62/21%/1% 14%/67%/18%/1%
LVEF (%) 29.7  8.5 28.3  7.6
Cardiac disease
Coronary 173 (75.5%) 173 (77.6%)
Cardiomyopathy 79 (34.5%) 84 (37.7%)
QRS duration (ms) 111.0  25.1 111.2  28.3
Conduction disorders
AV block 41 (17.9%) 32 (14.3%)
Bundle-branch block 36 (15.7%) 43 (19.3%)
Atrial rhythm disorder
Paroxysmal atrial ﬂutter 11 (4.8%) 2 (0.9%)
Atrial tachycardia 2 (0.9%) 6 (2.7%)
Paroxysmal atrial
ﬁbrillation
24 (10.5%) 25 (11.2%)
Associated conditions
Arterial hypertension 85 (37.1%) 96 (43.0%)
Diabetes 48 (21.0%) 53 (23.8%)
Drugs
Beta-blockers 186 (84.9%) 173 (82.0%)
ACE inhibitors/ARBs 178 (81.3%) 164 (77.7%)
Spironolactone 57 (26.0%) 45 (21.3)
Class III antiarrhythmic
agents
26 (11.9%) 24 (11.4%)
Values are mean  SD or n (%). Differences between the groups were not
statistically signiﬁcant.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker;
AV ¼ atrioventricular; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York
Heart Association.
FIGURE 2 Time to First Inappropriate Shock and to First Occurrence of
All-Cause Death or Cardiovascular Hospitalization
Kaplan-Meier analysis of (A) time to ﬁrst inappropriate shock and (B) time to ﬁrst
occurrence of all-cause death or cardiovascular hospitalization in patients with dual-
chamber (DC) settings (blue dotted line) and single-chamber (SC) settings (red line).
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615(p < 0.001). Figure 2B illustrates the occurrence of the
events over time.
SECONDARY ENDPOINTS. A total of 88 patients
(19.9%) received at least 1 ICD shock: 37 (16.1%) in the
dual-chamber setting group and 51 (22.9%) in the
single-chamber setting group (Table 3). The difference
in rates of patients with shocks was driven by a lower
frequency of patients with SVT-triggered inappro-
priate shocks in the dual-chamber setting group (1.3%)
compared with the single-chamber setting group
(7.6%) (p ¼ 0.001). The rates of patients with only
appropriate shocks were similar in both groups (11.7%
and 12.6% in the dual-chamber setting and single-
chamber setting groups, respectively).
Inappropriate shocks were delivered throughout
the 27-month follow-up period at a rate of 7.3%, with
no clustering at any speciﬁc time point. A total of 6
patients in the dual-chamber setting group (2.6%) and17 patients in the single-chamber setting group (7.6%)
received at least 1 inappropriate shock over 12 months
(p ¼ 0.015), as did 10 patients in the dual-chamber
setting group (4.3%) and 23 patients in the single-
chamber setting group (10.3%) at the end of the 27-
month period (p ¼ 0.015) (Table 3). The number of
patients needed to treat to prevent 1 patient from
experiencing an inappropriate shock was 17.
The reasons for inappropriate shocks in the 2
treatment groups included SVTs, responsible for
73.6% of the events, and lead failure or oversensing
in 25.5% of the events (Table 4). In patients in the
dual-chamber setting arm, lead failure or oversensing
was the major reason for inappropriate shocks
(70.8%). In patients in the single-chamber setting
arm, SVTs triggered 86.6% of all inappropriate
TABLE 3 Numbers a
Inappropriate Shocks
Variable
Patients receiving shoc
Patients with appropria
Patients with $1 inapp
Patients with $1 inapp
shock due to SVT
Patients with $1 inapp
shock for other rea
Values are n (%). *Chi-squ
SVT ¼ supraventricular t
TABLE 2 Numbers and Percents of Patients With Death and CV Events in
the 2 Treatment Groups
Variable
Total
(n ¼ 453)
Dual-Chamber
Setting Group
(n ¼ 230)
Single-Chamber
Setting Group
(n ¼ 223) p Value*
Death or CV event 96 (21.2%) 46 (20.0%) 50 (22.4%) NA†
Mortality 39 (8.6%) 21 (9.1%) 18 (8.1%) 0.688
CV event 73 (16.1%) 33 (14.3%) 40 (17.9%) 0.299
Hospitalization for HF 56 (12.4%) 25 (10.9%) 31 (13.9%) 0.327
Hospitalization for AF 23 (5.1%) 9 (3.9%) 14 (6.3%) 0.252
Stroke 3 (0.7%) 2 (0.9%) 1 (0.5%) 1.000
Undetected VT 1 (0.2%) 0 (0%) 1 (0.5%) 0.492
Values are n (%). *Chi-square test. †The primary endpoint was tested with an equivalence test. The cumulative
number of subitems exceeds the total number of patients with the composite endpoint because multiple criteria
of the composite were reached in some patients.
AF ¼ atrial ﬁbrillation; CV ¼ cardiovascular; HF ¼ heart failure; VT ¼ ventricular tachycardia.
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616shocks, compared with 29.2% of inappropriate shocks
in the dual-chamber setting group. A univariate
analysis was performed to assess the impact of
different factors (age, sex, left ventricular ejection
fraction, coronary artery disease, New York Heart
Association functional class, beta-blockers, angio-
tensin-converting enzyme inhibitors or angiotensin
receptor blockers, spironolactone, class III drugs,
treatment arm, implantation indication, and history
of AF) on the occurrence of inappropriate shocks.
Among these, only treatment arm, implantation
indication, and history of AF were added in a logistic
multivariate model and identiﬁed as independent
predictors (dual-chamber setting vs. single-chamber
setting odds ratio: 0.36; 95% CI: 0.17 to 0.80;
p ¼ 0.012; primary vs. secondary prevention of sud-
den cardiac death odds ratio: 0.38; 95% CI: 0.18
to 0.80; p ¼ 0.011; AF history absence vs. presence
odds ratio: 0.27; 95% CI: 0.11 to 0.63; p ¼ 0.003).
The rates of all-cause mortality were not statisti-
cally different (p ¼ 0.688) between the groups: 21
patients died in the dual-chamber setting groupnd Percents of Patients With Appropriate and
in the 2 Treatment Groups
Total
(n ¼ 453)
Dual-Chamber
Setting Group
(n ¼ 230)
Single-Chamber
Setting Group
(n ¼ 223) p Value*
ks 88 (19.9%) 37 (16.1%) 51 (22.9%) 0.068
te shocks only 55 (12.1%) 27 (11.7%) 28 (12.6%) 0.790
ropriate shock 33 (7.3%) 10 (4.3%) 23 (10.3%) 0.015
ropriate 20 (4.4%) 3 (1.3%) 17 (7.6%) 0.001
ropriate
sons†
14 (3.1%) 7 (3.0%) 7 (3.1%) 0.953
are test. †Lead failure, myopotential, oversensing, electromagnetic interference.
achyarrhythmia.(9.1%) and 18 patients in the single-chamber setting
group (8.1%). A breakdown of causes for cardiovas-
cular hospitalization is provided in Table 2.
Remarkably, ventricular pacing did not differ
signiﬁcantly between the groups, with a median of
0% in both groups (p ¼ 0.635) and means of 3.9 
13.8% in the dual-chamber setting group and 2.4 
8.6% in the single-chamber setting group. Atrial
pacing in the dual-chamber setting group was on
average 26.7  26.3% (median 17.2%).
SYSTEM-RELATED COMPLICATIONS. In the total
study population, 6 patients (1.3%) had atrial lead
complications, including dislodgment, perforation,
and loss of capture (Table 5). Twenty-one patients
(4.6%) had ventricular lead–related complications,
including fracture or insulation defect, dislodgment,
high ventricular threshold or loss of capture, and lead
perforation. Overall, 9 patients (2.0%) had hematoma,
9 patients (2.0%) had infections, and 6 patients (1.3%)
had pneumothoraces. No signiﬁcant difference was
observed between groups (even disqualifying the
atrial lead–related events in the single-chamber
setting group).
DISCUSSION
The OPTION trial is the ﬁrst prospective, randomized
study evaluating inappropriate shock occurrence
with dual-chamber settings and single-chamber set-
tings during long-term follow-up in an ICD popula-
tion. It shows a signiﬁcant reduction of inappropriate
shocks in the dual-chamber setting versus the single-
chamber setting arm, with equivalent rates of car-
diovascular events and death in both arms.
Conceptually, because of the information on atrial
rhythm, dual-chamber ICDs are expected to discrim-
inate more precisely between supraventricular and
ventricular tachyarrhythmias compared with single-
chamber ICD. Recent analyses of large-scale trials
point toward few inappropriate shocks with dual-
chamber ICDs, which may be less than with conven-
tional single-chamber ICDs (17,18). However, the
presumed superiority of dual-chamber ICD has
never been shown in prospective, randomized trials
for inappropriate shocks on per patient analysis
(19–22). The lack of statistical signiﬁcance in these
studies may be attributed to inadequate sample
sizes of early studies, study design, devices and al-
gorithms used, and device programming (single-zone
vs. multiple-zone programming). The results of our
trial add an important piece of evidence for the
reduction of inappropriate shocks with dual-chamber
ICDs (2.6% vs. 7.6% at 1 year, p ¼ 0.015; 4.3% vs.
10.3% at study end, p ¼ 0.012).
TABLE 5 Device- or Procedure-Related Adverse Events in the 2 Treatment Groups
Variable
Total
(n ¼ 453)
Dual-Chamber
Setting Group
(n ¼ 230)
Single-Chamber
Setting Group
(n ¼ 223)
Atrial lead* 6 (1.3%) 2 (0.9%) 4 (1.8%)
Fracture or insulation defect 0 0 0
Dislodgment 5 (1.1%) 1 (0.5%) 4 (1.8%)
Perforation 1 (0.2%) 0 1 (0.4%)
Loss of capture 1 (0.2%) 1 (0.5%) 0
High A threshold 0 0 0
Ventricular lead 21 (4.6%) 11 (4.8%) 10 (4.5%)
Fracture or insulation defect 9 (2.0%) 5 (2.2%) 4 (1.8%)
Dislodgment 7 (1.5%) 3 (1.3%) 4 (1.8%)
High V threshold /loss of RV capture 4 (0.8%) 2 (0.9%) 2 (0.9%)
Perforation 1 (0.2%) 1 (0.5%) 0
Oversensing† 10 (2.2%) 3 (1.3%) 7 (3.1%)
Pocket hematoma 9 (2%) 4 (1.7%) 5 (2.2%)
Skin perforation/infection/endocarditis 9 (2%) 3 (1.3%) 6 (2.7%)
Malfunctioning ICD 1 (0.2%) 1 (0.5%) 0
Cardiac tamponade 1 (0.2%) 1 (0.5%) 0
Pain at pocket requiring surgery 1 (0.2%) 0 1 (0.4%)
Pneumothorax 6 (1.3%) 0 6 (2.7%)
All‡ 59 (12.1%) 23 (10.0%) 36 (16.1%)
Values are n (%). *Patients in the single-chamber setting group would not have received atrial leads in clinical
practice. †6 due to myopotentials, 1 due to connecting problem, 1 due to electromagnetic interference, 1 due to
suspected lead failure, and 1 without documented reason. ‡In total, no signiﬁcant difference was observed be-
tween groups (p ¼ 0.052). A sensitivity analysis excluding atrial lead–related complications in the single-
chamber setting group conﬁrmed the absence of a signiﬁcant difference between groups (p ¼ 0.156).
ICD ¼ implantable cardioverter-deﬁbrillator; RV ¼ right ventricular.
TABLE 4 Reasons for Inappropriate Shocks in the 2 Treatment Groups
Variable
Total
(n ¼ 453)
Dual-Chamber
Setting Group
(n ¼ 230)
Single-Chamber
Setting Group
(n ¼ 223)
Number of inappropriate shocks 106 24 82
SVT 78 (73.6%) 7 (29.2%) 71 (86.6%)
Lead failure/oversensing 27 (25.5%) 17 (70.8%) 10 (12.2%)
Reason unknown 1 (0.9%) 0 1 (1.2%)
Values are n (%).
SVT ¼ supraventricular tachyarrhythmia.
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617The yearly rate of inappropriate shocks in OPTION
(2.6% in the dual-chamber setting group) was of the
same magnitude as in the recently conducted MADIT-
RIT (Multicenter Automated Deﬁbrillation Trial–
Reduction in Inappropriate Therapy) trial (31) and
lower than in several earlier large-scale trials, in
which rates of 11% to 13% were reported (12–20).
However, recent studies have reported very low
overall rates of inappropriate shocks, which may be
attributed to shorter follow-up periods, to speciﬁc
device settings, including a higher tachycardia ther-
apy cutoff rate, and to longer detection times (32–35).
Moreover, it should be noted that the high crossover
rate observed in our study from dual-chamber to
single-chamber therapy may have even diluted the
magnitude of the difference between the groups in
this intention-to-treat analysis. The rate of appro-
priate shocks in this trial was not signiﬁcantly
different between the groups, at 11.7% and 12.6% in
the dual-chamber setting and single-chamber setting
groups, respectively.
A second factor to be considered when deciding
between a dual-chamber or single-chamber device is
the detrimental effect of unnecessary right ventricu-
lar pacing on morbidity and mortality, which was
observed in the early days of dual-chamber ICD
therapy (24,36). In the meantime, this risk has been
substantially reduced by the introduction of algo-
rithms to minimize ventricular pacing (37–39). The
devices implanted within the OPTION trial were all
equipped with SafeR, a well-established algorithm to
minimize ventricular pacing, with proved effective-
ness in randomized clinical trials (30,38). In the
OPTION trial, no statistically signiﬁcant differences in
the percent of ventricular pacing was observed be-
tween the dual-chamber setting and single-chamber
setting groups, with a median ventricular pacing
percent of 0%. Furthermore, there were equivalent
rates of death or cardiovascular events in both
groups. Thus, dual-chamber ICD therapy combined
with the SafeR algorithm provides a net beneﬁt by
reducing inappropriate shocks without increasing
cardiovascular morbidity and mortality.
Finally, it is generally believed that the implanta-
tion of dual-chamber ICDs requires greater expertise.
There are reports of an increased incidence of im-
plantation- and device-related complications with
dual-chamber ICDs in current clinical care (23),
recently conﬁrmed by Peterson et al. (40). In contrast
to that and in agreement with the DATAS (Dual
Chamber and Atrial Tachyarrhythmias Adverse
Events Study) (41), the OPTION trial showed no
elevated incidence of device-related or implantation-
related adverse events in the dual-chamber group,even disregarding the atrial lead–related complica-
tions in the single-chamber group.
STUDY LIMITATIONS. All patients in the OPTION
study were provided with dual-chamber devices. This
could slightly overestimate the rates of inappropriate
shocks due to AF induced by local irritation from the
lead. This study design was chosen because the
information from the atrial lead was crucial to
determine accurately the appropriateness of the
therapy, which represented a central component of
our primary endpoint. Moreover, it should be noted
that the slow ventricular tachycardia zone setting was
different between the groups: this zone was used as a
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618monitor zone for the single-chamber group, while
ATP with no shock was recommended for the dual-
chamber group. Such a difference must be consid-
ered in addition to the treatment difference that is
under randomized investigation.
Given the small number of inappropriate shocks in
the dual-chamber setting group, further subgroup
analysis with respect to patients who may beneﬁt
most from dual-chamber implantation was not
possible.
The crossover rate was higher than in some other
studies. However, it is not assumed that this has
contributed to the positive ﬁnding of the trial,
because the vast majority of patients switched to the
dual-chamber setting group. This has rather diluted
the magnitude of the difference between the groups
in the intention-to-treat analysis.
The OPTION trial analyzed a speciﬁc setting
of algorithms enabled by Sorin devices, so the re-
sults may not be transferable to dual-chamber ICDs
from other manufacturers, which warrants further
investigation.CONCLUSIONS
The OPTION trial showed that therapy with dual-
chamber setting discrimination combined with algo-
rithms for minimizing ventricular pacing is associated
with reduced long-term risk for inappropriate shock
compared with single-chamber settings. The reduc-
tion of inappropriate shocks was obtained without an
increase in mortality, morbidity, or device-related
complications.
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